| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
Parathyroid hormone (PTH) 1-34 has capacity of enhancing bone formation. We hypothesized that the osteogenic capacity can be applied to enhance fracture healing. First, we investigated the effect of PTH treatment on human fracture haematoma-derived cells in vitro. PTH treatment did not affect cell proliferation. Osteogenic activity was also not significantly affected by continuous PTH treatment but significantly inhibited by pulsatile PTH treatment. Conversely, chondrogenic differentiation was significantly inhibited by continuous PTH treatment. Next, we conducted in vivo experiments. A rat fracture model which leads to nonunion by cauterization of periosteum was used. PTH was given to the rats by local and systemic administration. Although the local administration revealed no effect, the systemic administration demonstrated a tendency to enhance fracture healing. Our results suggested that a systemic administration was an appropriate way for a use of PTH to enhance fracture healing.
|
